Optimized Patency for Your Portal Hypertension Patients

PERFORMANCE through data

SUPERIOR TIPS PERFORMANCE

GORE® VIATORR®
TIPS ENDOPROSTHESIS
For your patients with portal hypertension, the GORE VIATORR® TIPS Endoprosthesis maintains significantly increased patency compared to bare metal stent alternatives. Highly effective in lowering portal pressure gradients in patients with refractory ascites and variceal bleeding, the GORE VIATORR® TIPS Endoprosthesis effectively treats patients over a longer period of time.

Two clinical studies were conducted in the United States to evaluate the GORE VIATORR® TIPS Endoprosthesis for use in de novo TIPS and TIPS revision. These studies demonstrated that primary patency of the GORE VIATORR® Device group was superior to that of the WALLSTENT® Device group (p < 0.001) at six months, with no significant differences in mortality or risk of encephalopathy*. Independent research since commercialization has yielded results that complement these original studies**.

* On file with Gore PMA P040027
** Data on file

Post-TIPS De Novo Hepatic Encephalopathy\cite{1, 2, 4, 6, 7, 8, 10, 12, 15, 18, 19, 21}

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{chart.png}
\caption{Comparison of hepatic encephalopathy rates between bare metal stents and GORE VIATORR® TIPS Endoprosthesis.}
\end{figure}
<table>
<thead>
<tr>
<th>YEAR</th>
<th>AUTHOR</th>
<th>N</th>
<th>0.5 YEAR</th>
<th>1 YEAR</th>
<th>2 YEAR</th>
</tr>
</thead>
<tbody>
<tr>
<td>2007</td>
<td>Bureau¹</td>
<td>39</td>
<td></td>
<td></td>
<td>76</td>
</tr>
<tr>
<td>2006</td>
<td>Amarapurkar²</td>
<td>11</td>
<td>90.9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2006</td>
<td>Rossle³</td>
<td>100</td>
<td>90</td>
<td>84</td>
<td></td>
</tr>
<tr>
<td>2006</td>
<td>Tripathi⁴</td>
<td>157</td>
<td>93</td>
<td>92</td>
<td>89</td>
</tr>
<tr>
<td>2005</td>
<td>Barrio⁵</td>
<td>20</td>
<td>100</td>
<td>100</td>
<td></td>
</tr>
<tr>
<td>2005</td>
<td>Echenagusia⁶</td>
<td>12</td>
<td>100</td>
<td></td>
<td>88.8</td>
</tr>
<tr>
<td>2005</td>
<td>Vignali⁷</td>
<td>113</td>
<td>91.9</td>
<td>79.9</td>
<td>75.9</td>
</tr>
<tr>
<td>2004</td>
<td>Angeloni⁸</td>
<td>32</td>
<td></td>
<td>76.3</td>
<td></td>
</tr>
<tr>
<td>2004</td>
<td>Charon⁹</td>
<td>100</td>
<td></td>
<td>84</td>
<td></td>
</tr>
<tr>
<td>2004</td>
<td>Hausegger¹⁰</td>
<td>71</td>
<td>87.4</td>
<td>80.8</td>
<td></td>
</tr>
<tr>
<td>2004</td>
<td>Maleaux¹¹</td>
<td>56</td>
<td></td>
<td>89.3</td>
<td></td>
</tr>
<tr>
<td>2004</td>
<td>Rossi¹²</td>
<td>53</td>
<td></td>
<td>83.8</td>
<td></td>
</tr>
<tr>
<td>2002</td>
<td>Otal¹³</td>
<td>20</td>
<td></td>
<td>80</td>
<td></td>
</tr>
<tr>
<td>2001</td>
<td>Cejna¹⁴</td>
<td>16</td>
<td></td>
<td>82</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Weighted Average</td>
<td></td>
<td>91.5</td>
<td>86.2</td>
<td>83.1</td>
</tr>
</tbody>
</table>
The GORE VIATORR® TIPS Endoprosthesis is indicated for use in the de novo and revision treatment of portal hypertension and its complications such as variceal bleeding, gastroesophageal reflux disease, and/or hepatic hydrothorax. Refer to Instructions for Use at goremedical.com for a complete description of all contraindications, warnings, precautions and adverse events.

Instructions for Use


